CL2012001852A1 - Uso de compuestos derivados de pirimidinil bencenosulfonamida, sus sales o sus hidratos, para tratar un trastorno de angiogénesis ocular, filtración vascular y degeneración macular relacionada con la edad (amd). - Google Patents

Uso de compuestos derivados de pirimidinil bencenosulfonamida, sus sales o sus hidratos, para tratar un trastorno de angiogénesis ocular, filtración vascular y degeneración macular relacionada con la edad (amd).

Info

Publication number
CL2012001852A1
CL2012001852A1 CL2012001852A CL2012001852A CL2012001852A1 CL 2012001852 A1 CL2012001852 A1 CL 2012001852A1 CL 2012001852 A CL2012001852 A CL 2012001852A CL 2012001852 A CL2012001852 A CL 2012001852A CL 2012001852 A1 CL2012001852 A1 CL 2012001852A1
Authority
CL
Chile
Prior art keywords
benzenesulfonamide
amd
pyrimidinyl
hydrates
age
Prior art date
Application number
CL2012001852A
Other languages
English (en)
Inventor
Iordache Valeriu Damian
Andrew King
Megan M Mclaughlin
Albert B Suttle
Original Assignee
Glaxo Wellcome Mfg Pte Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Limited filed Critical Glaxo Wellcome Mfg Pte Limited
Publication of CL2012001852A1 publication Critical patent/CL2012001852A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de compuestos derivados de pirimidinil bencenosulfonamida, sus sales o sus hidratos, para tratar un trastorno de angiogénesis ocular, filtración vascular y degeneración macular relacionada con la edad (AMD).
CL2012001852A 2010-01-06 2012-07-06 Uso de compuestos derivados de pirimidinil bencenosulfonamida, sus sales o sus hidratos, para tratar un trastorno de angiogénesis ocular, filtración vascular y degeneración macular relacionada con la edad (amd). CL2012001852A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06

Publications (1)

Publication Number Publication Date
CL2012001852A1 true CL2012001852A1 (es) 2012-11-30

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001852A CL2012001852A1 (es) 2010-01-06 2012-07-06 Uso de compuestos derivados de pirimidinil bencenosulfonamida, sus sales o sus hidratos, para tratar un trastorno de angiogénesis ocular, filtración vascular y degeneración macular relacionada con la edad (amd).

Country Status (20)

Country Link
US (1) US20130012531A1 (es)
EP (1) EP2521550A4 (es)
JP (1) JP2013516472A (es)
KR (1) KR20120125244A (es)
CN (1) CN102781450A (es)
AU (1) AU2011203706A1 (es)
BR (1) BR112012016673A2 (es)
CA (1) CA2786328A1 (es)
CL (1) CL2012001852A1 (es)
CO (1) CO6561789A2 (es)
DO (1) DOP2012000174A (es)
EA (1) EA201290603A1 (es)
IL (1) IL220594A0 (es)
MA (1) MA33991B1 (es)
MX (1) MX2012007875A (es)
PE (1) PE20121523A1 (es)
SG (1) SG181826A1 (es)
TW (1) TW201201808A (es)
UY (1) UY33164A (es)
WO (1) WO2011085007A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP3039424B1 (en) 2013-08-28 2020-07-29 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
EP3177289A4 (en) 2014-08-08 2018-03-21 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230574B1 (hu) * 2000-12-21 2023-11-28 Novartis Ag Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
WO2007064752A2 (en) * 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
EA201190337A1 (ru) * 2009-07-16 2012-06-29 Глаксо Вэллкам Мэньюфэкчуринг Пти Лтд. Способ лечения

Also Published As

Publication number Publication date
MX2012007875A (es) 2012-08-03
CO6561789A2 (es) 2012-11-15
CA2786328A1 (en) 2011-07-14
CN102781450A (zh) 2012-11-14
IL220594A0 (en) 2012-08-30
DOP2012000174A (es) 2012-12-15
EP2521550A1 (en) 2012-11-14
BR112012016673A2 (pt) 2018-06-05
EP2521550A4 (en) 2013-07-03
UY33164A (es) 2011-08-31
TW201201808A (en) 2012-01-16
EA201290603A1 (ru) 2013-03-29
KR20120125244A (ko) 2012-11-14
WO2011085007A1 (en) 2011-07-14
SG181826A1 (en) 2012-07-30
MA33991B1 (fr) 2013-02-01
AU2011203706A1 (en) 2012-07-12
JP2013516472A (ja) 2013-05-13
US20130012531A1 (en) 2013-01-10
PE20121523A1 (es) 2012-12-12

Similar Documents

Publication Publication Date Title
CL2012001852A1 (es) Uso de compuestos derivados de pirimidinil bencenosulfonamida, sus sales o sus hidratos, para tratar un trastorno de angiogénesis ocular, filtración vascular y degeneración macular relacionada con la edad (amd).
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
DK3466934T3 (da) Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft
EA201692000A1 (ru) Макроциклические производные пиридина
BR112017009470A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
UY36141A (es) Compuestos de fórmula (i), sus sales y composiciones que lo comprenden, para su uso en el tratamiento o prevención de enfermedades mediadas por el receptor cxcr2.
CR20120502A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
BR112016027455A2 (pt) moduladores ppar
MX2015005739A (es) Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.